Systemic Absorption and Pharmacokinetics of Five Novel Topical Dermatologic Agents: A Review

ABSTRACT In recent years, innovative topical medications with novel mechanisms of action have emerged to treat common dermatologic conditions such as acne, atopic dermatitis, vitiligo, and actinic keratoses. These molecularly targeted therapies offer improved safety and tolerability compared to traditional options like corticosteroids. This review examines the pharmacokinetics (PK), pharmacodynamics (PD), and systemic absorption of five such agents: ruxolitinib cream, tirbanibulin ointment, clascoterone cream, minocycline foam, and tapinarof cream. A literature review was conducted using SCOPUS and PubMed databases for articles published between January 2000 and January 2025. English‐language studies discussing the systemic absorption, pharmacodynamic, and pharmacokinetic profiles of these therapies were included. Studies consistently demonstrate low plasma concentrations and bioavailability for ruxolitinib 1.5% cream, tirbanibulin 1% ointment, clascoterone 1% cream, minocycline 4% foam, and tapinarof 1% cream, indicating minimal systemic absorption and a low risk of adverse effects. The introduction of promising new topical therapies such as ruxolitinib, tirbanibulin, clascoterone, minocycline, and tapinarof marks a significant advancement in dermatologic care. These agents improve safety, tolerability, and efficacy while broadening treatment options for diverse patient populations. Further research on long‐term safety and efficacy is needed to optimize their clinical use.